ACADIA Pharmaceuticals Company Insiders
ACAD Stock | USD 17.05 0.03 0.18% |
ACADIA Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding ACADIA Pharmaceuticals suggests that all insiders are panicking. ACADIA Pharmaceuticals employs about 597 people. The company is managed by 23 executives with a total tenure of roughly 12 years, averaging almost 0.0 years of service per executive, having 25.96 employees per reported executive.
Austin Kim President Executive Vice President General Counsel, Secretary |
ACADIA Pharmaceuticals' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-05-02 | Brendan Teehan | Disposed 3477 @ 16.94 | View | ||
2024-04-08 | Stephen Davis | Disposed 26574 @ 17.87 | View | ||
2024-03-27 | Stephen Davis | Disposed 17714 @ 17.9 | View | ||
2024-02-26 | Stephen Davis | Disposed 5577 @ 24.67 | View | ||
2024-01-08 | Brendan Teehan | Disposed 731 @ 29.96 | View | ||
2023-12-15 | James Kihara | Disposed 2000 @ 28.3 | View | ||
2023-11-20 | Brendan Teehan | Disposed 4960 @ 22.64 | View |
Monitoring ACADIA Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
ACADIA |
ACADIA Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with ACADIA Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that ACADIA will maintain a workforce of about 600 employees by June 2024.ACADIA Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.0686) % which means that it has lost $0.0686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1473) %, meaning that it created substantial loss on money invested by shareholders. ACADIA Pharmaceuticals' management efficiency ratios could be used to measure how well ACADIA Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of May 5, 2024, Return On Tangible Assets is expected to decline to -0.09. In addition to that, Return On Capital Employed is expected to decline to -0.16. At present, ACADIA Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 41 M, whereas Non Currrent Assets Other are forecasted to decline to about 2.6 M.The current year's Common Stock Shares Outstanding is expected to grow to about 172 M, whereas Net Loss is forecasted to decline to (204.1 M).
ACADIA Pharmaceuticals Workforce Comparison
ACADIA Pharmaceuticals is number one stock in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 602. ACADIA Pharmaceuticals totals roughly 597 in number of employees claiming about 99% of equities under Health Care industry.
ACADIA Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of (0.08) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.15 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.15.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.74 | 0.937 |
|
|
ACADIA Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ACADIA Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on ACADIA Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ACADIA Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-06-01 | 0.5 | 10 | 20 | 104,412 | 157,793 |
2024-03-01 | 1.1176 | 19 | 17 | 765,674 | 67,483 |
2023-12-01 | 0.6923 | 9 | 13 | 168,342 | 241,351 |
2023-09-01 | 0.1667 | 1 | 6 | 100,000 | 283,602 |
2023-06-01 | 1.7429 | 61 | 35 | 1,951,536 | 238,828 |
2023-03-01 | 0.65 | 13 | 20 | 359,357 | 94,973 |
2022-12-01 | 0.8333 | 5 | 6 | 37,996 | 21,134 |
2022-06-01 | 2.8333 | 34 | 12 | 1,486,512 | 46,155 |
2022-03-01 | 1.0667 | 16 | 15 | 60,640 | 33,538 |
2021-12-01 | 0.3125 | 5 | 16 | 70,668 | 208,313 |
2021-06-01 | 2.625 | 21 | 8 | 182,704 | 45,656 |
2021-03-01 | 1.3636 | 30 | 22 | 725,687 | 239,251 |
2020-12-01 | 0.5 | 5 | 10 | 26,406 | 43,388 |
2020-09-01 | 1.0 | 5 | 5 | 37,952 | 54,500 |
2020-06-01 | 0.75 | 30 | 40 | 585,154 | 1,071,679 |
2020-03-01 | 18.5 | 37 | 2 | 1,468,274 | 20,000 |
2019-12-01 | 0.4375 | 14 | 32 | 491,572 | 972,270 |
2019-09-01 | 0.8182 | 9 | 11 | 1,620,967 | 121,579 |
2019-06-01 | 3.0 | 15 | 5 | 754,512 | 504,256 |
2019-03-01 | 0.3333 | 1 | 3 | 10,000 | 120,000 |
2018-12-01 | 1.2727 | 14 | 11 | 12,264,484 | 545,843 |
2018-03-01 | 1.1429 | 8 | 7 | 159,500 | 285,379 |
2017-12-01 | 0.7 | 7 | 10 | 1,505,468 | 1,600,366 |
2017-09-01 | 1.625 | 13 | 8 | 682,301 | 144,352 |
2017-06-01 | 2.3333 | 7 | 3 | 105,996 | 17,899 |
2017-03-01 | 0.9375 | 15 | 16 | 1,066,504 | 416,942 |
2016-12-01 | 0.625 | 5 | 8 | 44,135 | 74,135 |
2016-09-01 | 2.25 | 9 | 4 | 1,520,030 | 22,682 |
2016-06-01 | 3.2 | 16 | 5 | 562,573 | 145,086 |
2016-03-01 | 12.5 | 25 | 2 | 7,390,602 | 14,000 |
2015-12-01 | 2.3333 | 7 | 3 | 310,000 | 44,000 |
2015-09-01 | 1.3333 | 4 | 3 | 250,500 | 25,500 |
2015-06-01 | 12.0 | 12 | 1 | 140,627 | 7,627 |
2015-03-01 | 1.1053 | 21 | 19 | 833,975 | 305,170 |
2014-12-01 | 0.65 | 13 | 20 | 246,060 | 394,120 |
2014-09-01 | 0.6316 | 12 | 19 | 581,882 | 408,764 |
2014-06-01 | 1.0417 | 25 | 24 | 310,592 | 359,184 |
2014-03-01 | 1.0588 | 18 | 17 | 1,345,316 | 456,000 |
2013-12-01 | 0.6667 | 14 | 21 | 229,309 | 383,118 |
2013-09-01 | 0.8214 | 23 | 28 | 624,016 | 798,761 |
2013-06-01 | 1.4 | 63 | 45 | 5,622,301 | 1,306,412 |
2013-03-01 | 0.7778 | 7 | 9 | 55,500 | 40,500 |
2012-12-01 | 0.5 | 3 | 6 | 43,631 | 70,602 |
2012-09-01 | 1.0 | 4 | 4 | 59,166 | 59,166 |
2010-03-01 | 0.5714 | 4 | 7 | 900,000 | 110,000 |
2009-09-01 | 1.0 | 2 | 2 | 20,000 | 20,000 |
2008-09-01 | 1.3333 | 4 | 3 | 22,000 | 21,000 |
2008-03-01 | 1.4167 | 17 | 12 | 263,000 | 36,000 |
2007-12-01 | 0.1818 | 4 | 22 | 23,500 | 62,000 |
2007-09-01 | 0.1212 | 4 | 33 | 12,500 | 57,528 |
2007-06-01 | 1.8571 | 13 | 7 | 101,308 | 48,834 |
2006-12-01 | 1.0 | 1 | 1 | 3,000 | 3,000 |
2006-09-01 | 0.6667 | 4 | 6 | 130,916 | 37,000 |
2006-06-01 | 6.5 | 13 | 2 | 210,014 | 28,000 |
2006-03-01 | 0.3636 | 4 | 11 | 122,000 | 106,000 |
2005-12-01 | 0.3333 | 2 | 6 | 40,500 | 65,500 |
2005-09-01 | 2.5 | 10 | 4 | 163,900 | 44,000 |
2004-06-01 | 0.7813 | 25 | 32 | 7,625,385 | 3,789,195 |
ACADIA Pharmaceuticals Notable Stakeholders
An ACADIA Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ACADIA Pharmaceuticals often face trade-offs trying to please all of them. ACADIA Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ACADIA Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Stephen JD | CEO President | Profile | |
Austin Kim | Executive Vice President General Counsel, Secretary | Profile | |
Mark Johnson | Vice President Investor Relations | Profile | |
Mark Schneyer | Executive CFO | Profile | |
Jennifer JD | Chief VP | Profile | |
MPH MD | Global SVP | Profile | |
Parag PharmD | Senior Franchise | Profile | |
Elizabeth Thompson | Executive Development | Profile | |
Bob Mischler | Senior Strategy | Profile | |
Albert Kildani | Senior Communications | Profile | |
Douglas MD | Executive Development | Profile | |
James Kihara | Chief VP | Profile | |
Kimberly Manhard | Senior Execution | Profile | |
Rob Ackles | Senior Officer | Profile | |
Julie Fisher | Senior Strategy | Profile | |
MSPH MD | President | Profile | |
Holly Valdiviez | Senior Sales | Profile | |
Brendan Teehan | COO VP | Profile | |
Erika Zavod | Planning, Strategy | Profile | |
Sanjeev MD | Senior Development | Profile | |
Kevin Oliver | Senior Officer | Profile | |
Stephanie Kim | Senior Affairs | Profile | |
Benir Ruano | Senior Operations | Profile |
About ACADIA Pharmaceuticals Management Performance
The success or failure of an entity such as ACADIA Pharmaceuticals often depends on how effective the management is. ACADIA Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ACADIA management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ACADIA management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.09) | (0.09) | |
Return On Capital Employed | (0.15) | (0.16) | |
Return On Assets | (0.08) | (0.09) | |
Return On Equity | (0.14) | (0.15) |
The data published in ACADIA Pharmaceuticals' official financial statements usually reflect ACADIA Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of ACADIA Pharmaceuticals. For example, before you start analyzing numbers published by ACADIA accountants, it's critical to develop an understanding of what ACADIA Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of ACADIA Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ACADIA Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ACADIA Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ACADIA Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of ACADIA Pharmaceuticals' management manipulating its earnings.
ACADIA Pharmaceuticals Workforce Analysis
Traditionally, organizations such as ACADIA Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ACADIA Pharmaceuticals within its industry.ACADIA Pharmaceuticals Manpower Efficiency
Return on ACADIA Pharmaceuticals Manpower
Revenue Per Employee | 1.2M | |
Revenue Per Executive | 31.6M | |
Net Loss Per Employee | 102.7K | |
Net Loss Per Executive | 2.7M | |
Working Capital Per Employee | 606.1K | |
Working Capital Per Executive | 15.7M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 4.434 | Quarterly Revenue Growth 0.693 | Return On Assets (0.07) | Return On Equity (0.15) |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.